Sign In
Buy NTLA
$13.02
-0.110 (-0.84%)
At Close: Jun 03, 2026
Why Intellia May Have Changed Medicine Forever
04:27pm, Friday, 02'nd Jul 2021
Genomics and gene editing is a sector that is truly in its infancy, but as we have seen this past week, that's not stopping investors from buying up companies in the sector at high valuations.
Intellia Therapeutics Announces Closing of $690 Million Public Offering of Common Stock
04:01pm, Friday, 02'nd Jul 2021
CAMBRIDGE, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/
Here's What Drove Gene Editing Stocks Higher This Week
12:48pm, Friday, 02'nd Jul 2021
The most exciting clinical trial data in the medical community has huge implications for Intellia, and its peers.
CRISPR gene-editing treatment could reach patients ‘very, very soon': Intellia CEO
10:46am, Friday, 02'nd Jul 2021
The trial success of CRISPR gene-editing technology has broad applications to treating other diseases, Intellia Therapeutics CEO John Leonard said.
Gene Editing Stocks Are Worth A Look After Intellia's Big Breakthrough
09:30am, Friday, 02'nd Jul 2021
Intellia Therapeutics - a gene-editing company co-founded by CRISPR pioneer and Nobel prize winner Jennifer Doudna - indicated that NTLA-2001, its experimental treatment for transthyretin amyloidosis
This Healthcare Breakthrough Gives Me Chills
05:02pm, Thursday, 01'st Jul 2021
In just the last few days, we got word of a healthcare game-changer that will save lives, eradicate much suffering and make investors money. The post This Healthcare Breakthrough Gives Me Chills appea
Intellia CEO on Crispr gene-editing treatment, secondary offering
03:58pm, Thursday, 01'st Jul 2021
Intellia Therapeutics president and CEO John Leonard joins 'Closing Bell' to discuss the clinical study of an experimental gene-editing treatment. The company also announced pricing of a secondary off
What's Happening With Intellia Therapeutics Stock?
09:30am, Thursday, 01'st Jul 2021
The stock price of Intellia Therapeutics, a biotechnology company developing treatments using a CRISPR gene-editing system, has seen a stellar 70% rise in just two trading days, after the company anno
What's Next For Alnylam Stock After The Recent Positive Development For Intellia?
08:30am, Thursday, 01'st Jul 2021
The stock price of Alnylam Pharmaceuticals, a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, has seen a 4.1% drop over the last five trading days, af
The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century
07:30am, Thursday, 01'st Jul 2021
Doudna's breakthrough in CRISPR has since ushered in a new era of genetic engineering, making these the best gene-editing stocks to buy. The post The Top 7 Gene-Editing Stocks to Buy for the Biggest S
Why Intellia Therapeutics Was a Winner on Wednesday
04:20pm, Wednesday, 30'th Jun 2021
The company is about to fatten its coffers significantly.
Gene Editing Stocks: Why EDIT, CRSP, NTLA Stocks Continue to Soar
02:12pm, Wednesday, 30'th Jun 2021
Today, gene editing stocks are soaring amid increasingly bullish sentiment in this sector following strong results from Intellia. The post Gene Editing Stocks: Why EDIT, CRSP, NTLA Stocks Continue to
Genomics ETFs Surge on a Major Breakthrough in CRISPR Study
02:04pm, Wednesday, 30'th Jun 2021
The genomic-editing space has come under the spotlight with the release of encouraging data from a study assessing an in vivo CRISPR-based gene editing therapy candidate, NTLA-2001.
NTLA Stock Price Increases Over 15%: Why It Happened
01:46pm, Wednesday, 30'th Jun 2021
The stock price of Intellia Therapeutics Inc (NASDAQ: NTLA) increased by over 15% during intraday trading. This is why it happened.
The 3 Biotech Firms Riding High on CRISPR News
01:37pm, Wednesday, 30'th Jun 2021
Biotech stocks can be risky. If a clinical trial fails, you could very well lose your money.
